manal A. Abbas

Prof. manal A. Abbas

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
MAmanal A. Abbas
manal A. Abbas

1 October 2020 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
MAmanal A. Abbas
manal A. Abbas

1 September 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MAmanal A. Abbas
manal A. Abbas
Mutasem TahaMutasem Taha
Mutasem Taha
ADAhmad M. Disi
Ahmad M. Disi
MSMaha Shomaf
Maha Shomaf

1 January 2019 in Research in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MAmanal A. Abbas
manal A. Abbas
MAManal Mohammad Abbas
Manal Mohammad Abbas
NANaseer Al-Rawi
Naseer Al-Rawi
IAIqbal Al-Khateeb
Iqbal Al-Khateeb
In the present investigation scratch wound assay was used to study the ability of several combinations of each flavonoid (chrysin, naringenin or resveratrol) with β-sitosterol to heal wounds in vitro. MTT test was performed to determine if the combination of flavonoid with β-sitosterol was toxic to fibroblasts or not. Also, superoxide dismutase (SOD) activity and interleukin-1ß (IL-1β) concentrations were measured. The best closure rates were obtained with β-sitosterol combined with naringenin and β-sitosterol combined with resveratrol. The combination that produced the best closure rate namely β-sitosterol with naringenin increased SOD activity significantly. However, this combination was not better than naringenin or β-sitosterol alone in reducing IL-β concentration. The results of MTT test indicated that the combination as well as β-sitosterol alone or naringenin alone has no toxic effect on fibroblasts. In conclusion, the combination of β-sitosterol and naringenin exerted a synergistic effect on wound closure without decreasing the viability of fibroblasts, increased antioxidant defense mechanism and decreased IL-β.

1 February 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MAmanal A. Abbas
manal A. Abbas
Mutasem TahaMutasem Taha
Mutasem Taha
MZMalek A. Zihlif
Malek A. Zihlif
ADAhmad M. Disi
Ahmad M. Disi

27 February 2020 in Balkan Medical Journal
Verified
Journal Article
Closed access
MAmanal A. Abbas
manal A. Abbas
Yasser Ibrahim KandilYasser Ibrahim Kandil
Yasser Ibrahim Kandil
MAManal Mohammad Abbas
Manal Mohammad Abbas
Doxorubicin is one of the most potent broad-spectrum antitumor and chemotherapeutic agents. However, it produces cardiotoxicity. To investigate whether R-(-)-carvone exerts a cardioprotective effect against doxorubicin toxicity in vivo and in vitro. Cell culture and animal experiment. The synergistic effect of R-(-)-carvone with doxorubicin was evaluated in the MCF 7 cancer cell line while its protective effect against doxorubicin toxicity was evaluated in the normal heart cell line (H9C2) and in vivo. Furthermore, the mechanism of its cardioprotective effect was studied. R-(-)-carvone exerted cytotoxic action on the MCF 7 cancer cell line with an IC50 value of 14.22 μM and potentiated the cytotoxic action of doxorubicin, while it decreased the toxicity of doxorubicin on a normal heart cell line. In BALB/c mice, R-(-)-carvone protected the heart from the toxic action of doxorubicin, as was evident by biochemical and histological studies. The protective effect of R-(-)-carvone on the H9C2 heart cell line and on heart in vivo was due to an increase in catalase activity. R-(-)-carvone has synergistic anticancer action with doxorubicin on the MCF 7 cell line while decreasing its cardiotoxicity.